File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/path.4832
- Scopus: eid_2-s2.0-85006141145
- PMID: 27770445
- WOS: WOS:000392844000003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy
Title | Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy |
---|---|
Authors | |
Keywords | cancer-associated fibroblast cytotoxic T lymphocyte dendritic cell DNA demethylating agents histone deacetylase inhibitors |
Issue Date | 2017 |
Publisher | John Wiley & Sons. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/1130 |
Citation | Journal of Pathology, 2017, v. 241 n. 1, p. 10-24 How to Cite? |
Abstract | The tumour microenvironment plays an instrumental role in cancer development, progression and treatment response/resistance. Accumulating evidence is underscoring the fundamental importance of epigenetic regulation in tumour immune evasion. Following many pioneering discoveries demonstrating malignant transformation through epigenetic anomalies (epimutations'), there is also a growing emphasis on elucidating aberrant epigenetic mechanisms that reprogramme the milieu of tumour-associated immune and stromal cells towards an immunosuppressive state. Pharmacological inhibition of DNA methylation and histone modifications can augment the efficiency of immune checkpoint blockage, and unleash anti-tumour T-cell responses. However, these non-specific agents also represent a double-edged sword', as they can also reactivate gene transcription of checkpoint molecules, interrupting immune surveillance programmes. By understanding the impact of epigenetic control on the tumour microenvironment, rational combinatorial epigenetic and checkpoint blockage therapies have the potential to harness the immune system for the treatment of cancer. Copyright (c) 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/273973 |
ISSN | 2021 Impact Factor: 9.883 2020 SCImago Journal Rankings: 2.964 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, M | - |
dc.contributor.author | Zhou, J | - |
dc.contributor.author | Chen, Z | - |
dc.contributor.author | Cheng, SL | - |
dc.date.accessioned | 2019-08-18T14:52:29Z | - |
dc.date.available | 2019-08-18T14:52:29Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Journal of Pathology, 2017, v. 241 n. 1, p. 10-24 | - |
dc.identifier.issn | 0022-3417 | - |
dc.identifier.uri | http://hdl.handle.net/10722/273973 | - |
dc.description.abstract | The tumour microenvironment plays an instrumental role in cancer development, progression and treatment response/resistance. Accumulating evidence is underscoring the fundamental importance of epigenetic regulation in tumour immune evasion. Following many pioneering discoveries demonstrating malignant transformation through epigenetic anomalies (epimutations'), there is also a growing emphasis on elucidating aberrant epigenetic mechanisms that reprogramme the milieu of tumour-associated immune and stromal cells towards an immunosuppressive state. Pharmacological inhibition of DNA methylation and histone modifications can augment the efficiency of immune checkpoint blockage, and unleash anti-tumour T-cell responses. However, these non-specific agents also represent a double-edged sword', as they can also reactivate gene transcription of checkpoint molecules, interrupting immune surveillance programmes. By understanding the impact of epigenetic control on the tumour microenvironment, rational combinatorial epigenetic and checkpoint blockage therapies have the potential to harness the immune system for the treatment of cancer. Copyright (c) 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. | - |
dc.language | eng | - |
dc.publisher | John Wiley & Sons. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/1130 | - |
dc.relation.ispartof | Journal of Pathology | - |
dc.subject | cancer-associated fibroblast | - |
dc.subject | cytotoxic T lymphocyte | - |
dc.subject | dendritic cell | - |
dc.subject | DNA demethylating agents | - |
dc.subject | histone deacetylase inhibitors | - |
dc.title | Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy | - |
dc.type | Article | - |
dc.identifier.email | Chen, Z: zchenai@hku.hk | - |
dc.identifier.authority | Chen, Z=rp00243 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1002/path.4832 | - |
dc.identifier.pmid | 27770445 | - |
dc.identifier.scopus | eid_2-s2.0-85006141145 | - |
dc.identifier.hkuros | 301450 | - |
dc.identifier.volume | 241 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 10 | - |
dc.identifier.epage | 24 | - |
dc.identifier.isi | WOS:000392844000003 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0022-3417 | - |